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group. The results show that VEGF-transfected BMSC as well 
as the combination of PRP and BMSC improve vasculariza-
tion, but bone healing was better with the combination of 
BMSC and PRP than with VEGF-transfected BMSC. Expres-
sion of VEGF in BMSC as a single growth factor does not seem 
to be as effective for bone formation as expanded BMSC 
alone or PRP which contains a mixture of growth factors. 
 Copyright © 2012 S. Karger AG, Basel 
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 Abstract 
 Both platelet-rich plasma (PRP) and vascular endothelial 
growth factor (VEGF) can promote regeneration. The aim of 
this study was to compare the effects of these two elements 
on bone formation and vascularization in combination with 
bone marrow stromal cells (BMSC) in a critical-size bone de-
fect in rabbits. The critical-size defects of the radius were 
filled with: (1) a calcium-deficient hydroxyapatite (CDHA) 
scaffold + phVEGF 165 -transfected BMSC (VEGF group), (2) 
CDHA and PRP, or (3) CDHA, autogenous BMSC, and PRP. As 
controls served: (4) the CDHA scaffold alone and (5) the 
CDHA scaffold and autogenous BMSC. The volume of new 
bone was measured by means of micro-CT scans, and vascu-
larization was assessed in histology after 16 weeks. Bone for-
mation was higher in the PRP + CDHA, BMSC + CDHA, and 
PRP + BMSC + CDHA groups than in the VEGF group (p  ! 
0.05). VEGF transfection significantly promoted vasculariza-
tion of the scaffolds in contrast to BMSC and PRP (p  ! 0.05), 
but was similar to the result of the CDHA + PRP + BMSC 
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Abbreviations used in this paper
-CT micro-computer tomography
BMSC bone marrow stromal cells
CDHA calcium-deficient hydroxyapatite
ECGF epithelial cell growth factor
EGF epidermal growth factor
FCS fetal calf serum
IGF insulin-like growth factor
NZWR New Zealand white rabbits
PBS phosphate-buffered saline
PDGF platelet-derived growth factor
PRP platelet-rich plasma
TGF transforming growth factor
VEGF vascular endothelial growth factor
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 Introduction 
 Healing large bone defects remains a major challenge 
in orthopedic surgery [Damien and Parsons, 1991; Ar-
rington et al., 1996]. As autogenously harvested bone 
transplants are limited and callus distraction is not fea-
sible in every defect site, alternative strategies involving 
the use of bone substitutes, bone marrow stromal cells 
(BMSC), and growth factors have successfully been ex-
plored [Niemeyer et al., 2009a, b; Janicki et al., 2010; Kas-
ten et al., 2010]. It is known that vascularization is impor-
tant and tightly regulated in bone healing [DePalma et al., 
1972; Burchardt and Enneking, 1978]. Healing occurs in 
three distinct but overlapping stages: (1) the early inflam-
matory stage, (2) the repair stage, and (3) the late remod-
eling stage [Bruder et al., 1994]. In the inflammatory 
stage of the first weeks the ingrowth of vascular tissue 
takes place and improves the nutrient and oxygen supply 
[DePalma et al., 1972; Burchardt and Enneking, 1978]. 
During the repair stage, fibroblasts begin to lay down a 
stroma that helps support vascular ingrowth [Laurencin 
et al., 1999]. As vascular ingrowth progresses, a collagen 
matrix is laid down while osteoid is secreted and subse-
quently mineralized, which leads to the formation of a 
soft callus around the repair site [DePalma et al., 1972; 
Burchardt and Enneking, 1978]. Fracture healing is com-
pleted during the remodeling stage in which the healing 
bone is restored to its original shape, structure, and me-
chanical strength. During this stage a stable and suffi-
cient vascular supply is formed. 
 As vascularity of the healing site is important during 
all stages, growth factors that improve vascularity have 
become increasingly popular. Vascular endothelial 
growth factor (VEGF), for example, has proven to in-
crease the blood supply [Geiger et al., 2007a]. The short 
half-life of VEGF (6–8 h), however, is considered prob-
lematic to achieve an effective level of growth factors. 
Therefore, a steady level of growth factor release at the site 
of the bony defect by viral transfection of BMSC has been 
investigated in the past [Geiger et al., 2007a]. Indeed, 
transfection of BMSC by the mammalian expression vec-
tor phVEGF 165 which contains the cDNA for recombi-
nant human VEGF 165 led to higher vascularization and 
faster resorption of the bone substitute [Geiger et al., 
2007a]. Another adjunct to improve bone healing is plate-
let-rich plasma (PRP) [Kasten et al., 2008a; Niemeyer et 
al., 2010]. PRP can easily be obtained on the day of sur-
gery by two centrifugation steps from autogenous whole 
blood. It contains not only VEGF but also a number of 
other growth factors like platelet-derived growth factor 
(PDGF), transforming growth factor (TGF)-  1 , TGF-  2 , 
insulin-like growth factor (IGF), epidermal growth factor 
(EGF), and endothelial cell growth factor (ECGF) in their 
natural composition [Kiuru et al., 1991; Kasten et al., 
2006; Vogel et al., 2006]. A critical-size bone defect can 
heal if, for example, bone substitutes are inserted into the 
defect [Puelacher et al., 1996; Marcacci et al., 1999; Wip-
permann et al., 1999]. In the present study a resorbable 
synthetic bone substitution material called calcium-defi-
cient hydroxyapatite (CDHA) was chosen as a scaffold 
whose surface area is approximately 50 m 2 /g, thus ap-
proaching the values of about 80 m 2 /g found in natural 
bone [Kasten et al., 2003]. 
 The two aforementioned concepts for improving 
bone healing (on one hand gene therapy with the use of 
transfected BMSC and on the other hand the use of a 
mix of natural growth factors from platelets) are com-
pletely different, and research groups often use either 
one or the other. The aim of this study was to compare 
these two concepts in terms of efficacy in one experi-
mental setting in a critical-size bone defect of the radius 
in rabbits. The hypothesis was that both concepts are 
equally effective in improving vascularization and fi-
nally bone healing.
 Material and Methods 
 Animals 
 According to the study protocol, the following groups (each 
n = 6) were compared: The critical-size defects of the radius were 
filled with: (1) a CDHA scaffold + phVEGF 165 -transfected BMSC 
(VEGF group), (2) CDHA and PRP, or (3) CDHA, autogenous 
BMSC, and PRP. As controls served: (4) the CDHA scaffold 
alone and (5) the CDHA scaffold and autogenous BMSC. Six- to 
9-month-old female New Zealand white rabbits (NZWR) were 
kept in separate cages; they were fed a standard diet and allowed 
to move freely during the study. Animals were treated in compli-
ance with our institution’s guiding principles ‘in the care and 
use of animals’. The local ethics committee for animal experi-
ments approved the design of the experiment. The groups PRP 
+ CDHA and PRP + BMSC + CDHA that were treated in paral-
lel were used for comparison [Kasten et al., 2008b]. One animal 
in the CDHA + PRP group sustained a fracture of the forearm 
and was excluded from the study.
 Ceramic Scaffolds and PRP 
 CDHA ceramic cylinders 15 mm in length and 4 mm in di-
ameter [Dr. h.c. Robert Mathys Foundation (RMS), Switzerland] 
were produced in an emulsion process as described earlier [Boh-
ner, 2000; LeGeros, 2002]. They have a specific surface area that 
approximates 48 m 2 /g with a total porosity or 85 vol% (54% mac-
ropores and 31% micropores). As published previously, for the 
preparation of PRP, on average 17 ml (SD 3.67) of blood was ob-
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tained from the ear arteries of six anesthetized 6-month-old 
NZWR [Kasten et al., 2008b]. The protocol was adapted from 
Yamada et al. [2004]. The blood was collected in tubes that were 
rinsed with heparin and the platelets were counted in Neuge-
bauer chambers. The average platelet number was 1.9  ! 10 8 /ml 
(SD 0.39  ! 10 8 ). Then, the blood was centrifuged twice: initial-
ly at 209  g for 16 min at 20  °  C to remove red blood cells and then 
at 1,500  g for 12 min at 20  °  C to obtain the platelet pellet. The cell 
pellet was suspended in platelet-poor plasma, resulting in an 
 average platelet number of 10.05  ! 10 8 /ml (SD 3.2  ! 10 8 ). The 
PRP of the six donors was mixed and stored at –80  °  C until need-
ed, and consequently allogenic and standardized PRP was 
used. 
 Bone Marrow Aspiration and BMSC Expansion 
 Bone marrow was aspirated and prepared from tibias from all 
rabbits about 18 days before surgery as described previously [Lou-
isia et al., 1999]. In brief, the surgical technique was as follows: 
with the animal under general anesthesia, the bone marrow of the 
tibia was penetrated antegradely via the proximal anterior tibial 
metaphysis using a sterile bone marrow aspiration needle with a 
diameter of 3 mm. After reaching the marrow space and remov-
ing the trocar, the bone marrow was aspirated using a 2-ml sy-
ringe containing 0.1 ml heparin. The aspirated marrow was mixed 
in a 15-ml Falcon tube containing 5 ml of predigestion medium 
[0.5 ml of collagenase (1.5 mg/ml), 0.5 ml of hyaluronidase (1 mg/
ml), and 4 ml of Verfaillie medium] [Reyes et al., 2001]. Then, the 
marrow aspirate was homogenized with a pipette. The aspirate 
was subsequently left to incubate at 39  °  C while spinning at 35 rpm 
continuously for 8 h (RM 540; CAT, Stauffen, Germany). Once 
digestion had ceased, 10 ml of phosphate-buffered saline (PBS) 
was added, and the predigested marrow aspirate was filtered us-
ing a 40-  m filter. The samples were washed in PBS (1: 2) and cen-
trifuged for 10 min at 677  g. Subsequently, the cells were counted 
and afterwards plated in cell culture flasks (Easy Flask filter, Nun-
clon TM surface; Nunc A/S, Roskilde, Denmark) in modified ex-
pansion medium according to Verfaillie with the addition of 2% 
fetal calf serum (FCS) [Reyes et al., 2001]. After 24 h, nonadhesive 
cells were discarded and adhesive cells were washed once with 
PBS. Standard culturing conditions were used (37   °   C, 5% CO 2 ), 
and the medium was changed twice a week. At 80–90% conflu-
ence, cells were harvested with trypsin/EDTA (Biochrom, Berlin, 
Germany) and replated by splitting usually 1: 3 at a density of 50–
60%. Cells were cultivated until passages 2–4, equaling 16–19 
population doublings. The mesenchymal differentiation poten-
tial for the osteogenic, the chondrogenic, and the adipogenic lin-
eages was demonstrated qualitatively in vitro from aliquots of the 
adherent cells of the bone marrow aspirate as reported previously 
[Vogel et al., 2006]. Therefore, the cells fulfill the criteria of mes-
enchymal stem/stromal cells [Reyes et al., 2001]. 
 Plasmid Preparation and Transfection of Rabbit BMSC 
 Human VEGF (GeneBank accession No. XM 004512) was in-
tegrated into the pCR3.1 plasmid (Invitrogen, Karlsruhe, Germa-
ny) as published previously [Nikol et al., 2002; Geiger et al., 2005] 
using the EcoRI restriction site. This resulted in a 5.6-kb vector 
containing the human VEGF 165 cDNA fragment, creating the 
plasmid phVEGF 165 . For large scale endotoxin-free plasmid DNA 
production of phVEGF 165 and pCR3.1, an EndoFree Plasmid Giga 
Kit (Qiagen, Hilden, Germany) was used according to the manu-
facturer’s protocol. Rabbit BMSC were cultured in cell culture 
flasks as described above under standard conditions (37   °   C with 
5% CO 2 ). For transfection, cells were seeded at 20  ! 10 3 cells/cm 2 
and allowed to adhere overnight. Transfection was performed 
with 1   g of plasmid DNA of phVEGF 165 or empty pCR3.1 com-
bined with 3   l of metafectene per 100.000 cells in serum-free 
medium. After 6 h the medium was changed to BMSC culture 
medium and cells were kept overnight. Transfected cells (5  ! 10 6 ) 
were then seeded on each scaffold.
 Loading of Cells and Application of PRP 
 All ceramics were incubated overnight at 4  °  C in 40   M /ml fi-
bronectin (Sigma, Taufkirchen, Germany) solution diluted in PBS 
to improve the adhesion of the cells and because it was found to 
be beneficial for bone formation [Vogel et al., 2006]. The cells to 
be transplanted were detached from the culture flasks by trypsin 
and counted. Five million cells were then resuspended in 3 ml of 
culture medium and transferred into a 5-ml tube. The ceramics 
were placed into the medium containing the cells. After 1.5 h of 
continuous spinning at 37   °   C (35 ! /min) to achieve a homoge-
neous distribution of the cells on the surface of the scaffold, the 
ceramics were placed into a six-well plate. The medium contain-
ing the cells was centrifuged twice at 800  g for 5 min, and the re-
sulting cell pellet was resuspended in 70   l of culture medium and 
applied to the ceramics. Previous studies demonstrated that load-
ing BMSC statically on CDHA had an efficiency of 95% [Kasten 
et al., 2005]. After loading of the cells, the BMSC remain in the 
superficial layers within a depth of 1–2 mm [Kasten et al., 2005]. 
As published previously, 40 ml of freshly thawed PRP was applied 
to the ceramics of the PRP group, and subsequently 10   l of 
thrombin (0.8 IU activity)-calcium chloride (1  M ) solution (1: 1) 
(Tissucol-duo; Baxter, Unterschleissheim, Germany) was added 
directly before implantation [Kasten et al., 2008b]. Animals that 
received PRP had no local inflammatory response, and no sys-
temic immune responses such as fevers were noticed [Kasten et 
al., 2008b].
 Surgical Procedure  
 The animal model was adapted from Wittbjer et al. [1982] as 
described previously. Briefly, unilateral 15-mm critical-size de-
fects were created in the distal radial diaphysis. The rabbits were 
anesthetized with an intramuscular injection of ketamine hydro-
chloride (50 mg/kg body weight, Hostaket  ; Intervet, Tönisvorst, 
Germany) and xylazine (5 mg/kg body weight, Rompun  ; Bayer 
Vital, Leverkusen, Germany). An antibiotic (netilmicin 4 mg/kg 
body weight, Certomycin  ; Essex Pharma, Munich, Germany) 
was administered perioperatively. A superomedial incision of
3 cm was made over the distal radius, soft tissues were dissected, 
and the bone was exposed by gentle retraction of the muscles. A 
Hohmann retractor was placed between the ulna and radius to 
protect the ulna. A 15-mm segmental diaphyseal defect was cre-
ated with an oscillating saw under irrigation with 0.9 vol% sterile 
saline solution. The periosteum was removed with the bone and 
5 mm of periosteum was stripped from each side of the remaining 
proximal as well as distal main fragment. The defect was irrigated 
with sterile physiological saline solution, and the scaffold was 
press fitted into the defect. Muscles, fascia, and skin were sepa-
rately closed over the defect with 4-0 resorbable sutures (Ethilon; 
Ethicon, Norderstedt, Germany). Fixation of the osteotomized ra-
dius was unnecessary because of the fibro-osseous union of ulna 
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and radius proximal and distal to the surgical site and the press 
fit of the implant. Although a certain micromotion of the implant 
might be possible due to resorption of the scaffold, no dislocation 
could be found in the subsequent control radiographs. Postopera-
tively, 4 mg/kg body weight of carprofen was given as needed for 
pain. There were no differences in carprofen administration 
among the groups. Water and food were supplied ad libitum. Af-
ter 16 weeks the animals were euthanized. Samples were excised 
en bloc with the surrounding soft tissues and immediately placed 
in paraformaldehyde 4%.
 Radiographic Evaluation 
 Standardized anterior-posterior and lateral radiographs were 
taken immediately postoperatively and every 4 weeks thereafter 
until sacrifice after week 16 to monitor the placement of the graft 
and the bony integration. An ultra-high-definition film (44 kV 
and 2.2 mA with a constant X-ray to object-to-film distance of 171 
cm) was used. No dislocation of the scaffold was noticed in this 
time period.
 Micro-Computer Tomography 
 Each specimen containing the 1.5-cm segmental defect and 
0.5 cm of proximal and 0.5 cm of distal cortical bone adjacent to 
the defect was examined with a micro-computer tomography (  -
CT) system (Fanbeam Micro-CT; Stratec, Stuttgart, Germany). 
The microfocus of the X-ray source of the   -CT system had a spot 
size of 7   m and a maximum voltage of 36 kV. The image matrix 
was 1,024  ! 1,024 pixels. The specimens were placed in a sample 
holder filled with water. They were oriented in such a way that the 
long axis of the block was parallel to the axis of the sample holder. 
A high-resolution protocol (slice thickness 120   m, feed 60   m, 
and pixel size 60   m) was applied. Depending on the length of the 
specimens, up to 180 slices were scanned perpendicular to the 
block. To determine the amount of newly formed bone tissue, the 
best threshold for the CDHA scaffold alone was selected visually 
followed by determination of the threshold for the CDHA scaffold 
and newly formed bone together. Furthermore, an empty cylinder 
of the scaffold and several bones were scanned prior to our inves-
tigation for comparison. In addition, the ranges and means of the 
gray levels characteristic of the CDHA scaffold and newly formed 
bone were determined. The CDHA scaffold showed a mean gray 
level of 160  8 15, while that of the newly formed bone was 60  8 
15. The visually determined threshold to separate the CDHA 
scaffold from newly formed bone was set at 100, allowing reliable 
distinction between the two tissue types. Finally,   -CT slices were 
compared with the corresponding histological slides to verify the 
reliability of the discrimination criteria. The digitized data were 
analyzed with VG Studio Max 1.2.1 software (Volume Graphics, 
Heidelberg, Germany), and the amount of new bone formation 
(newly formed bone voxels per complete tissue voxels of the ini-
tially implanted CDHA volume) was calculated. Resorption was 
calculated by dividing the voxels of the ceramic that was present 
after 16 weeks by the voxels of the mean of three CDHA cylinders 
that were not implanted. 
 Histology and Immunohistochemical Staining for Blood 
Vessels 
 After   -CT analysis, the nondecalcified specimens were de-
hydrated in ascending grades of alcohol and embedded in Tech-
novit (Technovit 7200 VLC; Kulzer GmbH, Wehrheim, Germa-
ny). During embedding, the positioning of the radius was stan-
dardized in an attempt to ensure that the same region was 
evaluated in all specimens. Then, 50-  m coronal sections with 
the radius and ulna parallel were made using a sawing and grind-
ing technique (Exakt Apparatebau, Hamburg, Germany). One 
section of each sample was stained with Giemsa and toluidine-
blue (Waldeck GmbH & Co., Division Chroma, Münster, Ger-
many) and three were used for immunohistological staining of 
the vessels. The sections were examined using a light microscope 
(Axioplan 2 Imaging; Zeiss, Göttingen, Germany). The Giemsa/
toluidine-stained specimens were digitized and analyzed with 
the program Image J (National Institutes of Health) [Abramoff 
et al., 2004]. The type of tissue was identified manually, marked, 
and assigned to a color. In detail, the areas of newly formed bone, 
connective tissue, and ceramic were calculated per total bone de-
fect area. 
 Endothelial cells were stained with a monoclonal mouse anti-
human CD-31 antibody (Clone: JC70A; DakoCytomation, Glas-
trup, Denmark; dilution 1: 20) as dexcribed previously [Geiger et 
al., 2007b]. The sections were deacrylated in two steps with 2-me-
thoxy ethyl acetate for 8h, incubated 3 times with XEM for 30 min, 
and rehydrated followed by digestion with 0.1% chymotrypsin 
(Sigma-Aldrich, Deisenhofen, Germany; 60 min, 37   °   C). Endog-
enous peroxidase was blocked by 3% hydrogen peroxide for 30 
min and nonspecific background was blocked using 5% BSA/PBS 
(30 min). Because the CD-31 antibody is specific for endothelial 
cells, vessels were stained with a monoclonal mouse anti-human 
CD-31 antibody (Clone: JC70A; DakoCytomation; dilution 1: 20) 
overnight at 4   °   C. Primary antibody was detected with the CSA 
biotin-free tyramide signal amplification system (DakoCytoma-
tion) according to the manufacturer’s instructions. Incubation 
with secondary antibody, anti-mouse-immunoglobulin-HRP, 
amplification reagent, and anti-fluorescein-HRP lasted 30 min 
each and incubation with DAB chromogen took 15 min. Counter-
staining was avoided due to possible influencing of the computer-
based image evaluation. 
 On each slide, six standardized regions of interest with an area 
of 0.6 mm 2 were photographed at a  ! 10 magnification with the 
Axioplan 2 (Carl-Zeiss, Oberkochen, Germany). Slices were ran-
domly selected before staining by a blinded investigator, and 
blood vessels were marked by two independent examiners blind-
ed for groups and treatment. The number of vessels in each region 
of interest was determined with the help of the Axiovision 4.4 
program (Carl-Zeiss). The mean values of the two observers for 
each parameter were calculated. 
 Statistics 
 Data analysis was performed with SPSS for Windows 15.0 
(SPSS, Inc., Chicago, Ill., USA). Mean values and standard devia-
tions were calculated. The main outcome measures were newly 
formed bone and ceramic resorption in   -CT and vessel forma-
tion in histology. These were examined by multifactorial analysis 
of variance (ANOVA). Differences between the independent vari-
ables were checked in post hoc tests [Tukey’s studentized range 
(HSD) tests for variables]. The alpha error was consequently ad-
justed. p  ! 0.05 was considered statistically significant. All tests 
were two-tailed. 
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 Results 
 Bone Formation in   -CT and Histology 
 Transfection of the BMSC with VEGF did not lead to 
a significant increase in bone formation as compared to 
CDHA controls ( fig. 1 ;  table 1 ). This was in contrast to 
the groups with PRP and BMSC that showed significant-
ly higher (p  ! 0.05) bone formation than the control 
CDHA group ( fig.  1 ). In detail   -CT analysis showed 
higher bone formation in the PRP group, with 24.8% of 
total CDHA cylinder volume (SD 5.5), and in the BMSC 
+ PRP group (26.7%, SD 6.3), as well as in the BMSC 
group (22.8%, SD 6), compared to the control CDHA 
group without cells (11%, SD 3.6) and the VEGF group 
(11.3%, SD 2) (p  ! 0.05). Analysis of the histology speci-
men showed that novel bone formation was mainly at the 
edges of the scaffold that were in close contact with the 
osteotomy surface of the radius ( fig. 2 ). Obviously, the 
environment in this area is most favorable for bone for-
mation due to direct cell contact and invasion from the 
adjacent bone. However, there was also bone formation 
within the pores of the scaffold ( fig. 2 a). Higher magni-
fication images were able to demonstrate direct osteo-
blast formation on the CDHA scaffold ( fig. 2 b). In his-
tology, there were no inflammatory reactions like
macrophages or lymphocyte aggregations visible due to 
biodegradation of the scaffold. 
 Biodegradation of the CDHA Scaffold 
 Biodegradation of the scaffold was increased over the 
course of 16 weeks in all groups compared to the CHDA 
control (p  ! 0.05). In the VEGF group the remaining ce-
ramic/total ceramic volume was 64.8% (SD 3.5), in the 
PRP group it was 57% (SD 7.2), in the PRP + BMSC group 
it was 60.2% (SD 7.9), and in the CDHA + BMSC group it 
was 61.8% (SD 5.8). The empty CDHA control had less 
biodegradation (75%, SD 8).
 Vascularization in Histology 
 VEGF transfection of the BMSC led to higher vascu-
larization of the scaffolds than in the BMSC and PRP 
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Table 1. N ew bone formation in -CT
Independent 
variable
Subgroup Mean value 8 SD (% of total 
CDHA cylinder volume)
n Post hoc
comparison*
p value†/
d.f./z value
Bone formation CDHA + VEGF transfected BMSC 1183.6 6 a 0.0001/4/13.86
in -CT CDHA + rabbit BMSC 22.8385.98 6 b
CDHA + PRP 24.885.54 5 b
CDHA + rabbit BMSC + PRP 26.6786.28 6 b
CDHA only 1183.58 6 a
* Different letters indicates significant differences between homogeneous subgroups at an alpha level of p < 0.05. For example, the 
VEGF group (post hoc comparison, letter a) is significantly different from CDHA + rabbit BMSC (letter b) but not from the CDHA 
only group (letter a). 
† By ANOVA.
 Fig. 1. There was a significantly higher (p  ! 0.05) bone formation 
measured in   -CT in the PRP group and the BMSC + PRP group 
as well as in the BMSC group compared to the control CDHA 
group without cells and the VEGF group. Asterisks indicate sig-
nificantly higher values compared to the CDHA and VEGF group. 
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groups (p  ! 0.05), but the result was similar to that of the 
CDHA + PRP + BMSC group ( fig. 3 ). The VEGF group 
had 21.31 vessels/mm 2 (SD 3.2) and the BMC + PRP group 
had 20.57 vessels/mm 2 (SD 6.71) compared to 13.06 ves-
sels/mm 2 (SD 0.93) in the CDHA control, 15.39 (SD 2.39) 
vessels/mm 2 in the BMSC group, and 16.02 vessels/mm 2 
(SD 6.71) in the PRP group ( fig. 3 ). Staining for CD-31 
displayed the vessels within the scaffold even in deeper 
areas of the biomaterial ( fig. 4 a, b).
 Discussion  
 The hypothesis of this study was that the osteogenic 
capacity of VEGF-transfected BMSC on a ceramic scaf-
fold in a critical-size long bone defect is equal to the addi-
tion of PRP and BMSC. A critical-size defect in this con-
text means that the defect cannot heal on its own in con-
trast to, for example, fractures. Our data demonstrates 
that VEGF-transfected BMSC and the combination of 
PRP and BMSC are equally effective in improving vascu-
0.5 mm 100 µm
1,000 µm
§
*
#
a b
c
 Fig. 2. This histology specimen (toluidine blue staining) from the VEGF group demonstrates bone formation 
at the edges of the CDHA scaffold (#) in close contact with the remaining native bone ( * ) ( a ). The lower magni-
fication ( a ) reveals bone formation within the pores of the scaffold (§). The higher magnification shows the di-
rect contact of the novel bone with the scaffold (arrow) and osteoblasts (arrowhead) ( b ).  c The figure shows the 
control of an empty CDHA scaffold that is not integrated into the bone and does not show any bony ingrowth. 
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larization, but bony healing was better in the combination 
of BMSC and PRP than with VEGF-transfected BMSC. 
 In general, the concept of tissue engineering is based 
on a combination of stem cells, biomaterials, and growth 
factors. In the current study the same high surface scaf-
fold CDHA was used to warrant comparison of the re-
sults. CDHA was chosen because it had shown favorable 
results in bone tissue engineering in the past [Kasten et 
al., 2005; Kasten et al., 2006; Kasten et al., 2008b]. Fur-
thermore, bone marrow-derived stem cells (BMSC) have 
been shown to improve bone regeneration in comparison 
to the use of biomaterials alone. Consequently, the bio-
material and BMSC was determined to be the control for 
this study. 
 A critical issue in bone regeneration is a sufficient vas-
cular supply as implantation of large bone grafts without 
adequate vascularity results in apoptosis and cartilage 
formation [Muschler et al., 2004]. This is supported by 
the fact that bone repair has been shown to benefit from 
increased angiogenesis [Santos and Reis, 2010]. The main 
focus of this study was to compare the effect of two ways 
to improve vascularization and subsequently bone regen-
eration. Firstly, VEGF-transfected BMSC and, secondly, 
a mix of growth factors derived from platelets (PRP) were 
used. 
 The growth factor VEGF has the potential to promote 
differentiation of common progenitor cells to angiogenic 
and osteogenic lineages. In embryonic development, 
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VEGFA has been considered of great importance for vas-
cularization and patterning of the bone growth plate 
[Gerber et al., 1999]. VEGFA has been shown to increase 
bone formation in long bone defect models [Street et al., 
2002; Geiger et al., 2005], promote osteoblast differentia-
tion in an autocrine fashion [Street et al., 2002], inhibit 
osteoblast apoptosis [Street and Lenehan, 2009], and in-
duce endothelial cells from human embryonic stem cells 
[Nourse et al., 2010]. Recently, it was shown that local ap-
plication of VEGFA to human adipose-derived stem cells 
significantly improved the healing of critical-size calvar-
ial defects in vivo and gene activated matrices (by VEGF) 
improved the healing of long bone defects in rabbits [Gei-
ger et al., 2005]. This repair was accompanied by an en-
hancement of angiogenesis [Behr et al., 2011]. Orchestra-
tion of bone formation is inevitably linked to a cross talk 
between osteoblasts and endothelial cells [Brandi and 
Collin-Osdoby, 2006]. An important mediator of angio-
genesis is VEGFA [Keramaris et al., 2008], which is phys-
iologically released during fracture healing [Street et al., 
2000]. A study demonstrated that VEGFA is primarily 
released by osteoblasts, whereas its action is conducted 
through endothelial cells [Clarkin et al., 2008]. Osteo-
genic effects of VEGFA on osteoblasts, such as increased 
bone nodule formation and alkaline phosphatase activity, 
have been reported in vitro [Street et al., 2002]. Moreover, 
VEGFA increased bone healing in vivo, whereupon deliv-
ery of VEGFA was performed with bioresorbable polylac-
tic acid depot scaffolds or gene-activated matrices [Street 
et al., 2002; Geiger et al., 2005].
 We are aware that the effect of a growth factor like 
VEGF is highly dependent on the method of administra-
tion, dosage, and other circumstances. This is why other 
authors found conflicting results on the effect of VEGF 
[Peng et al., 2002; Tarkka et al., 2003]. Our group has used 
different methods of administration in previous studies 
[Geiger et al., 2005, 2007b]. The way we used VEGF in 
this study has proven to be effective before [Geiger et al., 
2007b]. As we wanted to focus on the different effects of 
VEGF and PRP, we did not change the experimental set-
ting. Examination of other ways to use VEGF remains an 
interesting topic for future studies.
 Another popular way of improving vascularization, 
and subsequently bone formation, is PRP. In 1998, Marx 
et al. [1998] reported their initial results of PRP as a source 
of autogenous thrombocytic growth factors for the re-
construction of maxillofacial defects in humans. They 
found that PRP resulted in quicker maturation of autog-
enous bone transplants and higher bone density [Marx et 
al., 1998]. From basic science, we know that overall plate-
lets promote bone healing mainly by mitogenic effects, 
whereas the direct osteogenic effects are less pronounced 
[Kasten et al., 2008a]. The growth factors (PDGF, TGF, 
IGF, etc.) of the platelets are released after degranulation 
and act through a variety of pathways: the principal ac-
tions of PDGF are chemotaxis, mitogenesis, and angio-
genesis and start the bone healing cascade. The PDGF 
effect is exerted via receptors that have tyrosine kinase 
activity. IL-1, TNF-  , and TGF-  1 affect the binding of 
PDGF [Solheim, 1998]. TGF-  1 is not only released by 
platelets but also synthesized by osteoblasts and chondro-
cytes throughout the healing process. TGF-  activates 
the transformation of osteoprogenitor cells into osteo-
blasts, which in turn initiate the production of extracel-
lular matrix, or soft callus [Lieberman et al., 2002]. IGF-I 
promotes bone matrix formation (type I collagen and 
noncollagenous matrix proteins) by fully differentiated 
osteoblasts [Canalis, 1980] and is more potent than IGF-
II [Lieberman et al., 2002]. IGF-II acts at a later stage of 
endochondral bone formation and stimulates type I col-
lagen production, cartilage matrix synthesis, and cellular 
proliferation [Prisell et al., 1993]. 
 Besides the growth factors mentioned above, fibrin, 
fibronectin, and vitronectin play an important role as cell 
adhesions molecules. Fibronectin and vitronectin seem 
to be able to provide a foothold for cells as they move 
[Clark et al., 1982; Clark et al., 1996]. Fibrin is a cross-
linked protein derived from the fibrinogen in plasma. 
Like fibronectin and vitronectin, it contributes to cell 
movement in the wound. When fibrin cross-linking oc-
curs as part of the clotting process, it traps platelets and 
provides a scaffold or surface for cell movement.
 Recently there have been conflicting reports about the 
effect of PRP plasma, and there is no consensus regarding 
the role of PRP in bone regeneration: there are multiple 
favorable results of PRP regarding the improvement of 
proliferation of MSC in vitro and in vivo after ectopic 
implantation, but also in animal models with critical-size 
bone defects [Kasten et al., 2008b; Bi et al., 2010; Hakimi 
et al., 2010; Hartmann et al., 2010; Jungbluth et al., 2010; 
Niemeyer et al., 2010; Bae et al., 2011; Liu et al., 2011]. 
However, there is also a relevant number of studies re-
porting no or minimal effects of PRP on bone formation 
[Li et al., 2004; Roldan et al., 2004; Plachokova et al., 2007; 
Thor et al., 2007; Vasconcelos Gurgel et al., 2007; You et 
al., 2007; Miloro et al., 2010; Kazakos et al., 2011]. Regard-
ing its clinical use in maxillofacial surgery, a recent meta-
analysis indicated that there was sufficient evidence to 
support the use of PRP for bone formation on a sinus 
bone graft, whereas there was no significant effect on the 
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implant survival and bone-to-implant contact [Bae et al., 
2011]. In orthopedic surgery, some authors report posi-
tive outcomes in leg lengthening procedures and spinal 
fusions [Bi et al., 2010; Hartmann et al., 2010]. In sum-
mary, the role of PRP remains controversial. Several 
studies have shown a positive effect, mainly on early bone 
healing, while others have not. However, most studies can 
hardly be compared because the study designs were very 
different. Factors that can influence the efficacy of PRP 
as a promoter of bone healing are: (1) the biomaterial, (2) 
the species, (3) the site of implantation, and (4) the prepa-
ration and activation of the PRP.
 Rabbit thrombocytes have a survival time of 2–6 days 
and the growth factors are present for 1–2 days after de-
granulation. The platelet count in NZWR ranges from 
282  ! 103/mm 3 to 1,067  ! 103/mm 3 , with an average of 
563  ! 103/mm 3 in 100 normal rabbits [EBBE et al., 1965; 
Mitruka and Rawnley, 1977] 
 A key question in the interpretation of this study is 
why bone formation of VEGF-transfected cells was infe-
rior to the use of PRP. There are some possible explana-
tions for this finding. Although the selective increase of 
the single growth factor VEGF increased vascularization 
in histology, this did not translate into sufficient bone 
formation. This can be explained by the fact that bone 
healing relies on a ‘symphony’ of different growth factors 
that are secreted at different time points [Street et al., 
2000]. The mixture of growth factors of PRP obviously 
mimics nature better than a single growth factor, which 
might resulted in stronger bone formation after applica-
tion of PRP. Another explanation could be that plasmid 
transfection alters the BMSC in a way that reduces bone 
formation. Maybe the transfection inhibits transcription 
programs that are necessary for proper functioning and 
differentiation of the BMSC in bone healing. Similar phe-
nomena were reported after transfection of BMSC with 
growth differentiation factor-5 (GDF-5) for tendon re-
generation [Rickert et al., 2005].
 Conclusion 
 Expression of VEGF in BMSC as a single growth factor 
does not seem to be as effective as expanded BMSC alone 
or PRP for healing of a critical-size long bone defect in 
rabbits. The mixture of growth factors in PRP seems to 
be more useful for bone formation than the overexpres-
sion of a single growth factor that mainly increases vas-
cularization.
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